No Data
Rocket Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
CCORF Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $38
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $38 to $53
Small U.S. Stocks Move Upward; Rocket Pharmaceuticals Leads Increases
Rocket Pharma Gains on Trial Update for Gene Therapy
Rocket Pharmaceuticals Shares Are Trading Higher After the Company Announced That All Patients Have Bene Enrolled in the Global Phase 2 Clinical Trial Evaluating RP-A501 to Treat Male Patients With Danon Disease.